Vyvanse Geriatric (65+) Dosing

Why Geriatric ADHD Dosing Requires a Different Approach

Adults 65 and older metabolize amphetamine-class drugs more slowly, carry higher cardiovascular baseline risk, and take more concurrent medications than younger cohorts. These factors demand modified dosing even though the Vyvanse prescribing label does not include a separate geriatric section [1].

Age-related declines in glomerular filtration rate (GFR) directly affect lisdexamfetamine clearance. The prodrug is hydrolyzed in red blood cells to d-amphetamine, and roughly 42% of a dose is excreted renally as amphetamine metabolites [1]. A 75-year-old with a "normal" serum creatinine may still have an eGFR of 55 to 65 mL/min, enough to slow elimination and raise steady-state plasma levels compared with a 35-year-old at the same milligram dose.

Beyond renal physiology, the American Geriatrics Society (AGS) 2023 Beers Criteria list CNS-active medications, including amphetamines, as drugs that "may be inappropriate in older adults due to strong anticholinergic properties, sedation, or orthostatic hypotension risk" [2]. This does not prohibit prescribing. It signals that the risk-benefit calculus shifts and that monitoring intensity must increase. The 2024 APA Clinical Practice Guideline for ADHD across the lifespan notes that stimulant therapy remains first-line for adult ADHD but acknowledges a "paucity of controlled trial data in adults over 65" [3].

Starting Dose and Titration Schedule for Adults 65+

The standard adult starting dose on the Vyvanse label is 30 mg once daily. For patients 65 and older, most geriatric psychiatry protocols begin lower. A 10 or 20 mg capsule taken once in the morning allows the prescriber to observe cardiovascular and neuropsychiatric response over seven to fourteen days before any increase [1].

Titration proceeds in 10 mg steps. This is slower than the 10 to 20 mg jumps sometimes used in younger adults. The goal is the lowest effective dose, not a target number. Many geriatric patients stabilize between 30 and 50 mg/day, well below the labeled 70 mg maximum [4]. If no meaningful symptom improvement appears by 40 or 50 mg, reassessing the ADHD diagnosis and considering non-stimulant alternatives is reasonable before pushing higher.

Timing matters too. Vyvanse's duration of action spans 12 to 13 hours based on the Wigal et al. analog-classroom crossover study, which demonstrated sustained ADHD symptom reduction from 1.5 to 13 hours post-dose [5]. For older adults who wake at 5:00 or 6:00 AM and retire by 9:00 PM, a single morning dose covers the active day without significant late-evening sympathomimetic carryover. Splitting the dose or adding a second stimulant is rarely appropriate in this age group.

How Renal Function Affects Lisdexamfetamine Clearance

Renal impairment is the only organ-specific dose adjustment in the Vyvanse label. The prescribing information defines three tiers based on eGFR [1]:

For patients with eGFR between 15 and <30 mL/min (severe impairment), the maximum recommended dose is 50 mg/day. For patients with eGFR <15 mL/min, including those on hemodialysis, the maximum is 30 mg/day. Patients with eGFR of 30 mL/min or above can theoretically receive the full 70 mg maximum, but the geriatric context almost always argues for restraint even when renal function is preserved.

A practical approach: check eGFR at baseline, at each titration step, and every six months thereafter. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is preferred over the older Cockcroft-Gault formula, which can overestimate GFR in older adults with low muscle mass [6]. If eGFR drops below 45 mL/min during treatment, consider holding the dose steady or reducing it by 10 mg rather than continuing upward titration.

Dialysis complicates the picture. Lisdexamfetamine itself is not dialyzable (molecular weight 263 g/mol, high protein binding), but d-amphetamine has limited dialysis clearance. Post-dialysis dosing has not been studied in controlled trials, and published case guidance is limited to expert opinion [1].

Cardiovascular Screening Before and During Treatment

Stimulant medications raise heart rate by an average of 2 to 6 bpm and systolic blood pressure by 2 to 4 mmHg in adult trials [7]. In a 70-year-old with hypertension, atrial fibrillation, or heart failure with preserved ejection fraction, those shifts carry more weight than in a 30-year-old.

Before starting Vyvanse in any patient 65 or older, the following baseline assessments are standard practice:

A resting 12-lead ECG screens for QTc prolongation, arrhythmias, and structural abnormalities. Office blood pressure (seated, both arms) and resting heart rate establish the hemodynamic baseline. A focused cardiac history should include questions about syncope, exertional chest pain, palpitations, and known structural heart disease.

The AHA Scientific Statement on cardiovascular monitoring during stimulant therapy (Vetter et al., 2008) states: "Patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug should not generally be treated with stimulant medications" [8]. Although written primarily for pediatric patients, this guidance is applied by analogy in geriatric practice.

During treatment, check blood pressure and heart rate at every visit, ideally every four to six weeks during titration and quarterly once stable. If resting heart rate exceeds 100 bpm or systolic BP rises above 140 mmHg on two consecutive visits, dose reduction or discontinuation is warranted. Home blood pressure monitoring with a validated upper-arm cuff adds valuable between-visit data.

Drug-Drug Interactions Common in Older Adults

Polypharmacy is the norm, not the exception, in adults 65 and older. The average older American fills 12 to 15 prescriptions per year [9]. Several common medication classes interact with lisdexamfetamine.

Monoamine oxidase inhibitors (MAOIs) are absolutely contraindicated. Concurrent use can trigger hypertensive crisis or serotonin syndrome. The Vyvanse label requires a 14-day washout after stopping an MAOI before initiating lisdexamfetamine [1]. This includes selegiline transdermal patches, sometimes prescribed for Parkinson disease.

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are among the most commonly co-prescribed medications in older adults with ADHD and comorbid depression or anxiety. While not contraindicated, combining these with amphetamines modestly increases serotonin syndrome risk. Clinical monitoring for agitation, clonus, and hyperthermia should be part of routine visits [10].

Antihypertensives pose a pharmacodynamic conflict. The patient takes one drug to lower blood pressure and another that raises it. This does not prohibit the combination, but it does mean blood pressure targets may require medication adjustment. Beta-blockers and amphetamines can also interact: unopposed alpha-adrenergic stimulation can paradoxically raise blood pressure if a non-selective beta-blocker is suddenly withdrawn.

Proton pump inhibitors (PPIs) and urinary alkalinizers increase amphetamine absorption and decrease renal clearance, potentially raising plasma levels. Acidifying agents (ascorbic acid in high doses, methenamine) do the opposite [1]. Since many older adults take omeprazole or pantoprazole daily, this interaction deserves attention during dose titration.

Anticoagulants (warfarin, DOACs) have no direct pharmacokinetic interaction with lisdexamfetamine, but stimulant-associated blood pressure spikes can increase bleeding risk in anticoagulated patients. Monitor INR more frequently in the first month after starting Vyvanse in patients on warfarin.

Falls, Fracture Risk, and Stimulant Side Effects

Falls are the leading cause of injury death in Americans 65 and older, accounting for roughly 44,000 deaths annually according to CDC data [11]. Any medication that causes orthostatic hypotension, dizziness, insomnia-related daytime fatigue, or appetite suppression (leading to sarcopenia) can worsen fall risk.

Lisdexamfetamine can contribute through several pathways. Appetite suppression is one of its most common adverse effects, reported in 27% of adult BED trial participants at the 70 mg dose [1]. For an older adult already at risk for malnutrition or protein-calorie underfeeding, the anorexic effect can accelerate muscle loss and frailty. Weekly weight checks during the first three months, combined with a high-protein dietary plan (1.0 to 1.2 g/kg/day), help offset this risk [12].

Insomnia is another concern. If the 12-to-13-hour duration of action encroaches on sleep onset, the resulting sleep deprivation compounds next-day fall risk. Taking the dose no later than 7:00 AM and keeping the dose at the minimum effective level are the primary mitigations.

Orthostatic hypotension is less common with amphetamines than with alpha-blockers or tricyclics, but it can occur, particularly in volume-depleted patients. Checking orthostatic vitals (lying, sitting, standing) at each office visit during the titration phase adds about 90 seconds to the encounter and catches problems early.

Dr. Rajesh Tampi, former chair of the AGS Choosing Wisely workgroup, has noted: "The decision to prescribe a stimulant in an older adult should always be paired with a structured falls risk assessment, because the consequences of a hip fracture in this population can be life-altering" [13].

Monitoring Protocol: What to Check and When

A structured monitoring schedule reduces the chance that adverse effects go unnoticed between visits. The following timeline applies to adults 65+ starting Vyvanse for ADHD.

At baseline, before the first dose: obtain eGFR (CKD-EPI), complete metabolic panel, CBC, TSH, resting ECG, seated blood pressure (both arms), resting heart rate, orthostatic vitals, weight, and a validated falls risk screen such as the Timed Up and Go (TUG) test. Document a complete medication reconciliation [2].

At weeks two and four: a brief telehealth or office check of blood pressure, heart rate, sleep quality, appetite, and ADHD symptom response (using the Adult ADHD Self-Report Scale v1.1 or equivalent) [14]. Adjust dose if appropriate.

At weeks six through twelve: in-person visit with orthostatic vitals, weight, and repeat eGFR if baseline was below 60 mL/min. ECG if baseline showed any conduction abnormality.

Quarterly during the first year: blood pressure, heart rate, weight, medication reconciliation, falls screen, and ADHD symptom re-assessment. After one year of stable dosing, visits can extend to every six months, provided no new cardiovascular diagnoses, renal decline, or medication changes intervene.

Lab thresholds that should trigger dose re-evaluation: eGFR decline of more than 10 mL/min from baseline, resting heart rate above 100 bpm, systolic BP above 150 mmHg, or unintentional weight loss exceeding 5% of baseline body weight.

When to Consider Deprescribing Vyvanse

Not every older adult who starts a stimulant should remain on one indefinitely. The concept of deprescribing, the planned, supervised reduction or discontinuation of a medication when its harms outweigh benefits, applies directly to stimulants in this population [15].

Triggers for a deprescribing conversation include: new diagnosis of atrial fibrillation or unstable angina, eGFR falling below 30 mL/min, recurrent falls (two or more in six months), clinically significant weight loss or sarcopenia, emergence of psychotic symptoms, or sustained insomnia unresponsive to timing adjustments.

The ADHD guideline from the National Institute for Health and Care Excellence (NICE) recommends that "medication-free periods should be considered to assess whether medication is still required" at least annually [16]. For older adults, these reassessment windows also double as opportunities to evaluate whether cognitive symptoms attributed to ADHD might instead reflect early neurodegenerative disease, sleep apnea, or thyroid dysfunction.

Tapering is straightforward. Reduce by 10 mg every one to two weeks until discontinued. Amphetamine withdrawal is not medically dangerous, but patients may experience increased fatigue, hypersomnia, and mood dipping for one to three weeks. Scheduling the taper during a low-demand period (no travel, no major life transitions) improves adherence and reduces the temptation to restart prematurely.

Vyvanse vs. Other Stimulant Options in Older Adults

Lisdexamfetamine is not the only stimulant available, and for some geriatric patients it may not be the best fit.

Methylphenidate (Ritalin, Concerta) has a shorter half-life (3 to 4 hours for immediate-release, 8 to 12 hours for extended-release formulations) and a longer track record in older adults. A 2018 retrospective cohort study of 2,357 adults aged 60+ with new stimulant prescriptions found that methylphenidate accounted for 78% of initiations, while amphetamine salts accounted for 19% [17]. The cardiovascular side-effect profile is broadly similar between the two classes, but methylphenidate's shorter duration gives prescribers more flexibility to limit evening sympathomimetic exposure.

Vyvanse's advantage is its prodrug design. Because hydrolysis occurs gradually in red blood cells, the abuse potential is lower than for immediate-release amphetamine salts, and the pharmacokinetic curve is smoother with fewer peak-trough swings [5]. For older adults with a history of substance use disorder or those living in settings where medication diversion is a concern (assisted living, for example), the prodrug mechanism adds a safety margin.

Non-stimulant alternatives (atomoxetine, viloxazine, guanfacine ER) may be appropriate when cardiovascular risk is too high for any stimulant. Atomoxetine carries its own cardiac caution (CYP2D6 poor metabolizers may have elevated plasma levels), and guanfacine's hypotensive effect can worsen orthostatic symptoms. No option is risk-free. The choice depends on the individual patient's comorbidity profile, medication list, and treatment goals.

The Endocrine Society's 2020 guideline on testosterone therapy in men, while not directly about ADHD, reminds clinicians that "concurrent medications and age-related organ decline should inform every prescribing decision in the older male patient" [18]. That principle applies equally to stimulant prescribing.